145 related articles for article (PubMed ID: 30342473)
21. A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor.
McDermott DF; Trehu EG; Mier JW; Sorce D; Rand W; Ronayne L; Kappler K; Clancy M; Klempner M; Atkins MB
Clin Cancer Res; 1998 May; 4(5):1203-13. PubMed ID: 9607578
[TBL] [Abstract][Full Text] [Related]
22. [Clinical study on recombinant human interleukin-2 (Proleukin) in the treatment of metastatic renal cell carcinoma].
Sheng XN; Li JL; Guo J; Zhao XH; Zhu J; Chu DT
Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):129-33. PubMed ID: 18646697
[TBL] [Abstract][Full Text] [Related]
23. Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer.
Acquavella N; Kluger H; Rhee J; Farber L; Tara H; Ariyan S; Narayan D; Kelly W; Sznol M
J Immunother; 2008; 31(6):569-76. PubMed ID: 18528297
[TBL] [Abstract][Full Text] [Related]
24. Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer.
Quan WD; Quan FM; King LA; Walker PR
Cancer Biother Radiopharm; 2008 Feb; 23(1):108-13. PubMed ID: 18298334
[TBL] [Abstract][Full Text] [Related]
25. A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1.
Donskov F; Jensen NV; Smidt-Hansen T; Brøndum L; Geertsen P
Acta Oncol; 2018 May; 57(5):589-594. PubMed ID: 29392960
[TBL] [Abstract][Full Text] [Related]
26. Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma.
Bulgarelli J; Piccinini C; Petracci E; Pancisi E; Granato AM; de Rosa F; Guidoboni M; Petrini M; Ancarani V; Foschi G; Romeo A; Tontini L; De Giorgi U; Lolli C; Gentili G; Valmorri L; Rossi A; Ferroni F; Casadei C; Cortesi P; Crudi L; Ridolfi L
Front Immunol; 2021; 12():778459. PubMed ID: 34777395
[TBL] [Abstract][Full Text] [Related]
27. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
Alatrash G; Hutson TE; Molto L; Richmond A; Nemec C; Mekhail T; Elson P; Tannenbaum C; Olencki T; Finke J; Bukowski RM
J Clin Oncol; 2004 Jul; 22(14):2891-900. PubMed ID: 15254058
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of hu14.18-IL2 for patients with metastatic melanoma.
Albertini MR; Hank JA; Gadbaw B; Kostlevy J; Haldeman J; Schalch H; Gan J; Kim K; Eickhoff J; Gillies SD; Sondel PM
Cancer Immunol Immunother; 2012 Dec; 61(12):2261-71. PubMed ID: 22678096
[TBL] [Abstract][Full Text] [Related]
29. Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma.
Kuzman JA; Stenehjem DD; Merriman J; Agarwal AM; Patel SB; Hahn AW; Alex A; Albertson D; Gill DM; Agarwal N
BMC Urol; 2017 Jan; 17(1):1. PubMed ID: 28056941
[TBL] [Abstract][Full Text] [Related]
30. Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma.
Alwan LM; Grossmann K; Sageser D; Van Atta J; Agarwal N; Gilreath JA
Target Oncol; 2014 Mar; 9(1):63-71. PubMed ID: 23609056
[TBL] [Abstract][Full Text] [Related]
31. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
Tourani JM; Pfister C; Tubiana N; Ouldkaci M; Prevot G; Lucas V; Oudard S; Malet M; Cottu P; Ferrero JM; Mayeur D; Rixe O; Sun XS; Bernard O; Andre T; Tournigand C; Muracciole X; Guilhot J;
J Clin Oncol; 2003 Nov; 21(21):3987-94. PubMed ID: 14581421
[TBL] [Abstract][Full Text] [Related]
32. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer.
Kammula US; White DE; Rosenberg SA
Cancer; 1998 Aug; 83(4):797-805. PubMed ID: 9708948
[TBL] [Abstract][Full Text] [Related]
33. Clinical pathways for managing patients receiving interleukin 2.
Mavroukakis SA; Muehlbauer PM; White RL; Schwartzentruber DJ
Clin J Oncol Nurs; 2001; 5(5):207-17. PubMed ID: 11905416
[TBL] [Abstract][Full Text] [Related]
34. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma.
Cesana GC; DeRaffele G; Cohen S; Moroziewicz D; Mitcham J; Stoutenburg J; Cheung K; Hesdorffer C; Kim-Schulze S; Kaufman HL
J Clin Oncol; 2006 Mar; 24(7):1169-77. PubMed ID: 16505437
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency.
Kim KH; Kim HY; Kim HR; Sun JM; Lim HY; Lee HJ; Lee S; Bae WK; Rha SY; ;
Eur J Cancer; 2014 Mar; 50(4):746-52. PubMed ID: 24332573
[TBL] [Abstract][Full Text] [Related]
36. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
Gollob JA; Mier JW; Veenstra K; McDermott DF; Clancy D; Clancy M; Atkins MB
Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886
[TBL] [Abstract][Full Text] [Related]
37. Salvage-targeted kidney cancer therapy in patients progressing on high-dose interleukin-2 immunotherapy: the UCLA experience.
Birkhäuser FD; Pantuck AJ; Rampersaud EN; Wang X; Kroeger N; Pouliot F; Zomorodian N; Riss J; Li G; Kabbinavar FF; Belldegrun AS
Cancer J; 2013; 19(3):189-96. PubMed ID: 23708063
[TBL] [Abstract][Full Text] [Related]
38. A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma.
Mittelman A; Huberman M; Puccio C; Fallon B; Tessitore J; Savona S; Eyre R; Gafney E; Wick M; Skelos A
Cancer; 1990 Aug; 66(4):664-9. PubMed ID: 2386896
[TBL] [Abstract][Full Text] [Related]
39. A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma.
Monk P; Lam E; Mortazavi A; Kendra K; Lesinski GB; Mace TA; Geyer S; Carson WE; Tahiri S; Bhinder A; Clinton SK; Olencki T
J Immunother; 2014 Apr; 37(3):180-6. PubMed ID: 24598448
[TBL] [Abstract][Full Text] [Related]
40. Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870).
Pili R; Quinn DI; Hammers HJ; Monk P; George S; Dorff TB; Olencki T; Shen L; Orillion A; Lamonica D; Fragomeni RS; Szabo Z; Hutson A; Groman A; Perkins SM; Piekarz R; Carducci MA
Clin Cancer Res; 2017 Dec; 23(23):7199-7208. PubMed ID: 28939740
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
